Opendata, web and dolomites


A novel vaccine technology leading to accelerated availability of vaccines and improved delivery

Total Cost €


EC-Contrib. €






 VACCELERAID project word cloud

Explore the words cloud of the VACCELERAID project. It provides you a very rough idea of what is the project "VACCELERAID" about.

updated    accelerated    pharma    agreements    influenza    intended    introduction    companies    model    ing    gsk    dangerous    earlier    advantage    business    outbreaks    public    market    rna    seasonal    world    pose    fast    time    campaigns    area    view    marketing    full    sudden    demands    solutions    vaccine    approval    made    strategy    royalties    feasibility    licensing    regulatory    sanofi    payments    capsid    sv40    common    specified    hereto    highlight    additional    input    faster    offers    times    receive    lives    house    markets    self    evaluations    shortened    infectious    ip    co    initiation    start    gza    technologies    periods    wishes    risk    prepare    milestone    plan    nucleic    frequently    diseases    proteins    vaccines    vaccination    consuming    obtain    active    manufacturing    people    acid    validating    budget    unknown    validated    platform    professionals    attractiveness    met    health    definitely    pasteur    encounter    assembly    competitors    novartis    purpose    global    pandemics    delays   

Project "VACCELERAID" data sheet

The following table provides information about the project.


Organization address
address: SIRKIN 19
postcode: 53251
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-11-01   to  2017-04-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GEZA AD LTD IL (GIVATAIYM) coordinator 50˙000.00


 Project objective

Common to current manufacturing technologies for vaccines is the long lead-time before they were made available or novel vaccines could be made available to the public. Current methods are very time consuming and frequently encounter problems with scale-up, in particular if sudden demands have to be met. However, the ability to start vaccination campaigns fast – and earlier than currently possible – is particularly important in view of seasonal influenza, influenza pandemics or sudden outbreaks of dangerous, hereto unknown infectious diseases. Resulting delays definitely pose a high risk for health and lives of many people. To provide solutions to these world-wide challenges is of European and global interest and GZA offers such a response: The technology is based on self-assembly of SV40 capsid proteins around a given nucleic acid and has several additional applications; however, it will be validated here in the area of vaccination with RNA. The main advantage of GZA’s novel vaccine technology platform is that it enables strongly shortened manufacturing periods and accelerated market introduction of a novel vaccine (e.g., 2-3 times faster manufacturing for novel influenza vaccines). The business model is based on developing and validating the technology for a given purpose in-house and receive milestone payments and royalties specified in co-development and licensing agreements with established pharma companies active in the vaccine sector (such as GSK, Novartis or Sanofi Pasteur). Most importantly, in the feasibility assessment applied for here GZA wishes to further detail the business plan with updated evaluations of markets, competitors, IP, a project/development plan and budget to further highlight the attractiveness of the business case and to prepare initiation of a full development program in phase 2. Furthermore, it is intended to obtain input from experienced regulatory professionals and draft a potential regulatory strategy aiming at marketing approval.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VACCELERAID" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VACCELERAID" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More  


ENDOSCAPE, a clinically applicable non-viral gene delivery technology

Read More